Skip to main content
. 2015 Feb 1;8(2):1545–1554.

Figure 4.

Figure 4

Expressions of miR-101 and VEGF in serum. N: healthy controls; B: benign; M: malignant. A: The serum miR-101 level in three different groups. B: The serum VEGF level in three different groups. C: The serum VEGF level in malignant PCC with SDHD mutation and non-SDHD mutation.